Statin use is associated with new-onset type 2 diabetes. It is on the FDA label. What that means for an older adult, and what it does not mean.
This is a documented, labeled association, and it is a trade-off rather than a prohibition. Both halves of that sentence matter.
What is established
- The FDA added a class-wide safety label change on February 28, 2012 warning of increased HbA1c and fasting glucose with statin use.
- Sattar et al., The Lancet, 2010 — a collaborative meta-analysis of randomized statin trials found roughly a 9% increase in incident diabetes.
- The Lancet Diabetes & Endocrinology, 2024 — an individual-participant-data meta-analysis confirming new-onset diabetes and worsening glycemia.
Where the risk concentrates
It is higher with intensive dosing, and it concentrates in people already near the diabetes threshold — which in a long-term care population is a large share of residents. Someone with a fasting glucose in the prediabetic range on a high-intensity statin is the person this actually describes.
What it is not
It is not a reason to stop a statin. The American College of Cardiology’s position is that the cardiovascular benefit still outweighs this risk for patients at meaningful cardiovascular risk. Presenting a labeled side effect as a reason to discontinue a drug that is preventing strokes would be a worse error than not mentioning it at all.
What it is
A fact that belongs in the conversation, particularly in an older adult where the calculation has moved. The questions worth asking a prescriber are whether the intensity is still right, whether the time to benefit still fits, and whether glycemia is being monitored on the assumption that this can happen rather than on the assumption that it will not.
Time to benefit is the question the STOPPFrail criteria exist for, and it is a legitimate one in a resident with limited life expectancy. Deprescribing in long-term care.
Nobody should stop a statin because of this article. It is a question for the prescriber, with the whole cardiovascular picture in front of them.
The evidence, with the numbers
The 2010 collaborative meta-analysis pooled 13 randomized statin trials and 91,140 participants, of whom 4,278 developed diabetes over a mean of four years. Statin therapy was associated with a 9% increased risk of incident diabetes, odds ratio 1.09 (95% CI 1.02 to 1.17), with little heterogeneity between trials. In absolute terms: treating 255 patients (95% CI 150 to 852) for four years produced one extra case of diabetes. Meta-regression found the risk was highest in trials with older participants — which is the population this site is about.
The 2024 individual-participant-data meta-analysis from the Cholesterol Treatment Trialists’ Collaboration is the current and more precise source. Across 19 statin-versus-placebo trials (123,940 participants) and four more-versus-less-intensive trials (30,724):
- Low or moderate intensity statin: a 10% proportional increase in new-onset diabetes (1.3% per year versus 1.2% per year; rate ratio 1.10, 95% CI 1.04 to 1.16).
- High intensity statin: a 36% proportional increase (4.8% per year versus 3.5% per year; rate ratio 1.36, 95% CI 1.25 to 1.48).
- About 62% of new-onset diabetes cases were in participants already in the top quarter of the baseline glycemia distribution. The effect is concentrated in people who were already close to the threshold.
- In people who already had diabetes, worsening glycemia: rate ratio 1.10 (1.06 to 1.14) at low or moderate intensity, 1.24 (1.06 to 1.44) at high intensity.
What is on the label
The current FDA-approved labeling carries it as a warning and precaution: “Increases in HbA1c and fasting serum glucose levels have been reported with statins,” with the advice to “optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.” This is a labeled, acknowledged effect, not a contested claim.
And the sentence that has to travel with it
The CTT authors state directly that “any theoretical adverse effects of statins on cardiovascular risk that might arise from these small increases in glycaemia … are already accounted for in the overall reduction in cardiovascular risk that is seen with statin therapy in these trials.” The 2010 meta-analysis said the same: the risk is low in absolute terms and against the reduction in coronary events, and “clinical practice in patients with moderate or high cardiovascular risk or existing cardiovascular disease should not change.”
This is a fact for the conversation with the prescriber — about intensity, about monitoring, and about time to benefit in a resident with limited life expectancy. It is not a reason for anyone to stop a statin.
References
- Sattar N, Preiss D, Murray HM, et al. 2010. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716):735-42. [meta-analysis, 13 trials, 91,140 participants] · PMID 20167359 · doi:10.1016/S0140-6736(09)61965-6
- Cholesterol Treatment Trialists’ (CTT) Collaboration 2024. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes & Endocrinology 12(5):306-319. [individual-participant-data meta-analysis] · PMID 38554713 · doi:10.1016/S2213-8587(24)00040-8
- US Food and Drug Administration 2024. LIPITOR (atorvastatin calcium) prescribing information, section 5.4: increases in HbA1c and fasting serum glucose levels. FDA-approved label, effective 2024-04-15. [FDA-approved drug label] · Source
- Curtin D, Gallagher P, O’Mahony D 2021. Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2. Age and Ageing 50(2):465-471. [Delphi-validated criteria] · PMID 32997135 · doi:10.1093/ageing/afaa159